Obesity Medicine

Latest News

Switching to Tirzepatide Outweighs Escalating Dulaglutide Dose in T2D: SURPASS-SWITCH Trial
Switching to Tirzepatide Outweighs Escalating Dulaglutide Dose in T2D: SURPASS-SWITCH Trial

April 4th 2025

Breaking research presented at ACP Internal Medicine 2025 showed that switching GLP1-RAs resulted in better glucose and weight control among adults with inadequately controlled T2D.

Responsive Parenting Intervention Curbs Childhood Obesity Risk: Daily Dose / image credit: ©New Africa/AdobeStock
Responsive Parenting Intervention Curbs Childhood Obesity Risk: Daily Dose

April 3rd 2025

ACC 2025: Cardiovascular Benefits of Semaglutide 2.4 mg Highlighted in Real-World Study
ACC 2025: Cardiovascular Benefits of Semaglutide 2.4 mg Highlighted in Real-World Study

April 1st 2025

CagriSema Achieves Significant Weight Loss in Phase 3 Trial: Daily Dose / image credit: ©New Africa/AdobeStock
CagriSema Achieves Significant Weight Loss in Phase 3 Trial: Daily Dose

March 31st 2025

Viking Therapeutics Completes Enrollment for Phase 2 Trial of Oral Tablet for Obesity / image credit ©Viking Therapeutics
Viking Therapeutics Completes Enrollment for Phase 2 Trial of Oral Obesity Tablet

March 26th 2025

© 2025 MJH Life Sciences

All rights reserved.